Portopulmonary hypertension: Survival and prognostic factors

American Journal of Respiratory and Critical Care Medicine

Volumn 178, Issue 6, 2008, Pages 637-643

  Le Pavec, Jérôme ^a,c   Souza, Rogério ^a   Herve, Philippe ^a   Lebrec, Didier ^b   Savale, Laurent ^a   Tcherakian, Colas ^a   Jaïs, Xavier ^a   Yaïci, Azzedine ^a   Humbert, Marc ^a   Simonneau, Gérald ^a   Sitbon, Olivier ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Cirrhosis; Portal hypertension; Portopulmonary hypertension; Pulmonary hypertension; Survival

Indexed keywords

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; AUTOIMMUNE DISEASE; BUDD CHIARI SYNDROME; CARDIOPULMONARY HEMODYNAMICS; CAUSE OF DEATH; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HEART INDEX; HEMOCHROMATOSIS; HUMAN; LIVER CIRRHOSIS; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATIENT ASSESSMENT; PATIENT REFERRAL; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SCHISTOSOMIASIS; SURVIVAL RATE; SURVIVAL TIME; VIRUS HEPATITIS; WALKING;

ADULT; FEMALE; FRANCE; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; KAPLAN-MEIERS ESTIMATE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULAR RESISTANCE; VENTRICULAR FUNCTION, RIGHT;

EID: 51849110348     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200804-613OC     Document Type: Article

References (35)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-117.
2. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-1665.
3. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004;24:861-880.
4. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-528.
5. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, Cortese DA, Wiesner RH. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996;71:543-551.
6. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, Mal H, Bernuau J, Marty J, Lebrec D, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003;37:401-409.
7. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030.
8. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443-450.
9. Krowka MJ, Swanson KL. How should we treat portopulmonary hypertension? Eur Respir J 2006;28:466-467.
10. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991;17:492-498.
11. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, Palevsky HI. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005;11:1107-1111.
12. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-1166.
13. Sakuma M, Nakamura M, Nakanishi N, Miyahara Y, Tanabe N, Yamada N, Kuriyama T, Kunieda T, Sugimoto T, Nakano T, et al. Clinical characteristics, diagnosis and management of patients with pulmonary thromboembolism who are not diagnosed in the acute phase and not classified as chronic thromboembolic pulmonary hypertension. Circ J 2005;69:1009-1015.
14. Le Pavec J, Souza R, Boutet K, Jaïs X, Tcherakian C, Humbert M, Hervé P, Simonneau G, Sitbon O. Prognostic factors in portopulmonary hypertension [abstract]. Eur Respir J 2007;30:548s.
15. Le Pavec J, Souza R, Jais X, Cabrol S, Herve P, Humbert M, Simonneau G, Sitbon O. Prognostic factors in portopulmonary hypertension [abstract]. Proc Am Thorac Soc 2006;3:A728.
16. Lebrec D. Methods to evaluate portal hypertension. Gastroenterol Clin North Am 1992;21:41-59.
17. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor D, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-923.
18. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111.
19. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-2278.
20. Kuo PC, Plotkin JS, Johnson LB, Howell CD, Laurin JM, Bartlett ST, Rubin LJ. Distinctive clinical features of portopulmonary hypertension. Chest 1997;112:980-986.
21. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
22. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788.
23. Kawut SM, Krowka MJ, Trotter F, Roberts KE, Benza RL, Badesh DB, Taichman DB, Horn EM, Zachs S, Kaplowitz N, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008;48:196-203.
24. Benhamou JP, Erlinger S. Maladies du foie et des voies biliaires, 4th ed. Paris: Medecine Sciences Flammarion; 1999.
25. Terrier B, Tamby M, Camoin L, Guilpain P, Broussard C, Bussone G, Yaici A, Hotellier F, Simonneau G, Guillevin L, Humbert M, Mouthon L. Identification of target antigens of anti-fibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;177:1128-1134.
26. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-648.
27. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-508.
28. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004;10:945-950.
29. Kawut SM. Caring for the orphan's orphan: treatment of patients with portopulmonary hypertension. Eur Respir J 2007;30:1038-1040.
30. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-1502.
31. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-863.
32. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, Welte T, Halank M. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007;30:1096-1102.
33. Findlay JY, Plevak DJ, Krowka MJ, Sack EM, Porayko MK. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999;5:362-365.
34. Golbin JM, Krowka MJ. Portopulmonary hypertension. Clin Chest Med 2007;28:203-218.
35. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, Ramsay M, Davis GL. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007;7:1258-1264.